HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Real-World Data One Of Five Areas For Improvement For EU Digital Self-Care Regulation

Executive Summary

The AESGP in a new position paper calls for a flexible regulatory framework to unlock the "tremendous opportunity" of digital innovation in self-care. 

You may also be interested in...



HBW Insight’s Key Takeaways From 2021: #3 Keep Your Eye On AI

The future of digital health will be shaped more than anything else by the rise of artificial intelligence. From body enhancing bio-wearables to camera-based skin diagnostics, the consumer health industry continued to explore the possibilities presented by AI in 2021. However, there are many regulatory and ethical hurdles industry must overcome as we move into 2022 and beyond.

PAGB Digital Week, Day 2: Real-World Evidence And Its Potential In Consumer Healthcare

Day two of PAGB's Digital Week explored potential applications for real world evidence in the consumer healthcare industry, such as generating new claims for established products and to help support prescription-to-OTC switches.

J&J’s Nicorette QuickMist SmartTrack – Getting Inside One Of 2020’s Biggest UK Launches

HBW Insight speaks to Johnson & Johnson's Bill Twomey and Sven Sjovall about how one of the biggest OTC launches of 2020 – Nicorette QuickMist SmartTrack – uses behavioral science techniques to help motivate consumers to quit smoking and overcame COVID-related supply chain difficulties to launch a much-needed digital smoking cessation aid in the middle of a pandemic. 

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS151313

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel